A

Amgen

Makes biotech medicines for serious illnesses

Data Engineer

Full-TimeUpdated on 10/24/2026
No salary listed
Senior
Bachelor's, Master's
Hyderabad, Telangana, India
In Person
Data & AnalyticsData Engineering

About the job

Requirements
  • A Master's or Bachelor's degree in Computer Science, Information Technology, Engineering, Data Science, or a related field, with 5–8 years of relevant professional experience.
  • Hands-on experience with Databricks, Apache Spark, PySpark, Spark SQL, Python, and SQL.
  • Experience designing, developing, and supporting production ETL/ELT pipelines.
  • Experience with workflow orchestration and scheduled data-processing workloads.
  • Strong understanding of data modeling, data warehousing, lakehouse architecture, and data-integration concepts.
  • Experience working with large and complex datasets.
  • Experience with Spark and SQL performance tuning.
  • Experience with AWS or another major cloud platform.
  • Experience with Git, CI/CD, automated testing, and production deployment.
  • Experience implementing data-quality, metadata, lineage, and governance controls.
  • Understanding of role-based access control, data privacy, security, and compliance requirements.
  • Strong analytical and troubleshooting skills.
  • Experience working in Agile delivery environments.
  • Strong verbal and written communication skills.
  • Ability to work effectively with global and cross-functional teams.
  • High degree of initiative, ownership, and attention to detail.
  • Ability to manage multiple priorities and meet delivery commitments.
  • Ability to clearly present technical information to technical and non-technical audiences.
Responsibilities
  • Design, develop, test, and maintain scalable data pipelines and data-integration solutions.
  • Build ETL/ELT processes for structured, semi-structured, and unstructured data.
  • Integrate data from enterprise applications, databases, APIs, cloud platforms, and third-party systems.
  • Contribute to the technical design and implementation of end-to-end data solutions.
  • Develop reusable and maintainable Python, PySpark, Spark SQL, and SQL components.
  • Implement data-quality checks, validation rules, reconciliation processes, logging, and exception handling.
  • Optimize Spark workloads, SQL queries, partitioning, and data-processing performance.
  • Develop and maintain data models, data dictionaries, mappings, and technical documentation.
  • Implement data-security, privacy, governance, and role-based access requirements.
  • Support workflow orchestration, scheduling, monitoring, alerting, and recovery processes.
  • Contribute to CI/CD pipelines, automated testing, version control, and deployment processes.
  • Troubleshoot data-pipeline failures, performance issues, and data-quality problems.
  • Collaborate with data architects, business subject-matter experts, analysts, data scientists, product teams, and DevOps teams.
  • Participate in sprint planning, backlog refinement, technical estimation, and delivery activities.
  • Take ownership of assigned data-engineering work from development through deployment and production support.
  • Evaluate new technologies and recommend improvements to data-engineering processes and platform performance.
  • Follow coding, testing, documentation, security, and reusable-development standards.
  • Participate in operational support activities, including occasional off-hours support.
Desired Qualifications
  • Experience in biotechnology, pharmaceutical, life sciences, manufacturing, or another regulated industry.
  • Experience with Delta Lake, Unity Catalog, Databricks Workflows, or comparable technologies.
  • Experience with AWS data, storage, integration, security, and monitoring services.
  • Experience developing APIs or data services for downstream consumers.
  • Experience with relational, NoSQL, analytical, or vector databases.
  • Experience with data visualization tools such as Tableau or Power BI.
  • Experience supporting machine-learning or AI data pipelines.
  • Experience designing or developing Generative AI solutions using large language models, Retrieval-Augmented Generation, embeddings, vector search, prompt engineering, or governed enterprise data.
  • Familiarity with AI-assisted development tools such as GitHub Copilot, OpenAI Codex, or equivalent platforms.
  • Databricks Certified Data Engineer Associate certification.
  • AWS Certified Data Engineer or another relevant cloud certification.
  • Relevant data engineering, analytics, or Agile certification.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.

Yahoo Finance
Oct 21st, 2026
Amgen's focus shifts to six growth drivers and MariTide as rare disease sales hit $1.6B

Amgen now frames its story around six key growth drivers, which grew 26% from a year earlier in fiscal Q2 2026 and made up nearly 70% of product sales. Rare disease, once reported on its own, is one of the six. The rare disease portfolio grew 21% to $1.6 billion, about 16% of quarterly revenue. Total revenue rose 9.5%, and management raised its 2026 revenue guidance to between $38.2 billion and $39.4 billion. Management also highlighted MariTide, an obesity drug in Phase III trials. Amgen wants it to be the first monthly or less frequent obesity therapy and is already scaling up manufacturing. One risk sits in rare disease. On September 1, 2026, Britain's medicines regulator suspended Tavneos for new patients, citing an unreliable main study. The drug made $119 million in fiscal Q1 2026. Amgen's next report is expected around November 3, 2026.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Amgen raises 2026 revenue forecast to $38.8B as shares gain 15.2%

Amgen raised its fiscal 2026 revenue forecast on August 4 to $38.8 billion at the midpoint, up 2.6% from $37.8 billion. Adjusted earnings per share guidance rose to $22.90 from $22.40. Six key growth drugs grew 26% from a year earlier and made up nearly 70% of product sales in the June quarter. Repatha sales rose 37% to $953 million, offsetting a 33% drop in Prolia and XGEVA sales as biosimilar copies launched. Total revenue rose 10%. The stock has gained 15.2% since the release, against 1.9% for the S&P 500. It closed at $434.03 on October 15, above both its 50-day and 200-day averages. Reaching the midpoint requires $20.1 billion in the second half. Amgen's next report is expected around November 3.